Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Meet the real people of color behind Houston’s effort to educate about PrEP and TasP.
A new analysis of the global START trial found that health outcomes were better for those starting treatment within six months.
A look at what the law says about buying prescription drugs from Canada.
After almost a decade on antiretroviral therapy, half of study participants still had HIV in immune cells in their brain and spinal fluid.
Investigators led by Scripps Research will study vaccines that coax the immune system into creating antibodies that protect against HIV.
Electronic prompts for clinicians to recommend Truvada to people at risk for HIV could help increase PrEP’s impact.
Researchers compared outcomes between babies born to HIV-positive mothers exposed to antiretrovirals and those who were not.
LatinX+ will enable Latinx PLHIV to “define their own agenda.”
PrEP use increased across regions and demographic groups but remains lower among Black and Latino men.
The money will help fund Birmingham’s efforts to achieve the UNAIDS 90-90-90 treatment goals.
Long-term salvage therapy without NRTIs suppressed HIV in nearly 80% of those who remained in care.
Researchers compared data on more than 9,000 people with HIV who took either version of tenofovir.
Previous research has shown that long interruptions are not safe—but what about shorter, more closely monitored gaps in treatment?
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.